LEXICON PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2022-03-10
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-09-30 was 10.19M shares, a 1.67% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2019-09-30 was 10.37M shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-09-30 was 0.00 shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 0.00 shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 10.37M shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-10 | ||
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-09 | 0.00 shares 10-Q · filed 2021-11-09 | |
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-10 | ||
| 2020-09-30 | 10.19M shares 10-Q · filed 2021-11-09 | 0.00 shares 10-Q · filed 2021-11-09 | |
| 2019-12-31 | 10.37M shares 10-K · filed 2022-03-10 | ||
| 2019-09-30 | 10.37M shares 10-Q · filed 2020-10-30 | 10.37M shares 10-Q · filed 2020-10-30 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2021-03-12 | ||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-07 | 0.00 shares 10-Q · filed 2019-11-07 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2020-03-12 | ||
| 2015-12-31 | 10.37M shares 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |